Inhibition of SIRT1 has been shown to reduce estrogen-induced cell growth and tumor development, indicating that combining SIRT1 inhibitors with antiestrogen therapies could offer more effective treatment strategies for HR+ breast cancer [73]. This evidence concerns the gene SIRT1 and neoplasm.